The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments. Both
Tilos Therapeutics is involved in the development of therapeutics, which targets the latent TGFβ complex to treat cancer, fibrosis and autoimmune diseases. TGFβ is a potent cytokine supposed
All six patients were recruited and treated under this protocol. All primary safety objectives have been achieved at the midpoint in all study participants. As such, the protocol
In January 2017, Acucela had received orphan drug designation from the US Food and Drug Administration (FDA) for emixustat to treat Stargardt disease. Stargardt disease is a rare
“Extending the life of transplanted kidneys would mean fewer patients going back on dialysis or needing a second transplant – relieving pressure on waiting lists that in the
Under the deal, Exonics equity holders will receive $245m (£192m) upfront payment from Vertex, as well as potential future payments based on the achievement of specified development and
ADPKD is the most common inherited form of kidney disease affecting approximately 140,000 patients in the United States. It is characterized by the development of pathologic fluid-filled cysts
Emgality, which is an advanced therapeutic approach for the neurologic disease, is claimed to be the first and only calcitonin gene-related peptide (CGRP) antibody approved by the FDA
These latest results show a durable and sustained OS benefit in patients with unresectable, Stage III NSCLC who had not progressed following concurrent chemoradiation therapy (CRT), a previous
The company has revealed the positive topline data from two phase III multicentre studies assessing Xolair to treat adults with CRSwNP who have not adequately responded to intranasal
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.